MedTrace Logo

Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

NCT03486080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2021-05-27

No results posted yet for this study

Summary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction

Conditions

  • Acute Myocardial Infarction
  • Acute Myocardial Ischemia
  • STEMI - ST Elevation Myocardial Infarction

Interventions

DRUG

Dutogliptin Tartrate

Active treatment

DRUG

Filgrastim Injectable Product

Active treatment

DRUG

Placebos

placebo control

Sponsors & Collaborators

  • Recardio, Inc.

    lead INDUSTRY

Principal Investigators

  • Roman Schenk, MD · Recardio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-07
Primary Completion
2021-02-26
Completion
2021-02-26
FDA Drug
Yes

Countries

  • Austria
  • Belgium
  • Hungary
  • Netherlands
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03486080 on ClinicalTrials.gov